Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.
about
New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilastAnti-TNF agents for paediatric psoriasisAnti-TNF agents for paediatric psoriasisProfile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasisLeukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory diseaseNew era of biologic therapeutics in atopic dermatitisCardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.In-vivo imaging of psoriatic lesions with polarization multispectral dermoscopy and multiphoton microscopyBiological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implicationsClinical nonlinear laser imaging of human skin: a review.Biological drugs for the treatment of psoriasis in a public health system.Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab.Etanercept biosimilarsMDcons: Intermolecular contact maps as a tool to analyze the interface of protein complexes from molecular dynamics trajectoriesCharge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.Effect of TNF-α inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and Toll-like receptors-2 and -9 in psoriatic plaques.Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targetsThe risk of herpes zoster in the anti-TNF-α era: a case report and review of the literature.HLA-C, DRB1 and DQB1 alleles involved in genetic predisposition to psoriasis vulgaris in the Slovak population.Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.East Indian Sandalwood Oil (EISO) Alleviates Inflammatory and Proliferative Pathologies of Psoriasis.Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity.Briakinumab for the treatment of plaque psoriasis.Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence.Selectins and their ligands as potential immunotherapeutic targets in neurological diseases.Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response.Conformationally constrained peptides from CD2 to modulate protein-protein interactions between CD2 and CD58.Ultrasound in psoriatic arthritis. Can it facilitate a best routine practice in the diagnosis and management of psoriatic arthritis?A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.Impact of pregnancy and oestrogen on psoriasis and potential therapeutic use of selective oestrogen receptor modulators for psoriasis.Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis.Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.The Th17/IL-23 Axis and Natural Immunity in Psoriatic ArthritisVisual Loss Induced by Adalimumab Used for Plaque Psoriasis.Latent virus reactivation risk and biological drugs: chronic inflammatory and immune-mediated disorders.Patient reports of the frequency and severity of adverse reactions associated with biological agents prescribed for psoriasis in Brazil.Reactivation of human polyomavirus JC in patients affected by psoriasis vulgaris and psoriatic arthritis and treated with biological drugs: preliminary results.Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis.
P2860
Q22305855-CF6436A8-C994-4C18-A8F4-020C8D3C56BAQ24187673-B887F362-F3C0-46F1-9E96-380356296423Q24201907-7A7A3CFF-50F8-401A-B45C-C1F856FB3FD7Q26765028-C85E8CD0-FEB8-4395-B315-C45BAEBEE078Q26822941-FED29269-AA04-4E29-B065-D362FC11E902Q27001941-66AA4D27-26C3-4932-A0A2-16D1D572DD22Q33823950-585A89E9-EB97-4C7B-BF3C-14F11C8E69D2Q33915866-BDC095DB-18CC-4B30-BF68-589E917EBA51Q34099814-C0C9198B-A5B6-4A0D-8773-223E8FF7E0B5Q34177011-EF3A7F3B-9D62-4E7C-A8FE-8A6C367E060AQ34271894-EA560551-9BE9-47FD-919E-A730502C9B07Q34502118-3AC58166-D3A3-496D-8143-D29833FC31C3Q35020358-ECD046E6-7C91-4256-8B97-487F9B73F348Q35215905-2E1CE783-536B-496D-81E7-E5BD80069B62Q35616449-B7F89FCA-4F11-49B2-BA1C-6317A6DDE3C2Q36080973-053EC5F7-93C2-4E4F-BA3E-BCA975AAE635Q36158922-874BD3FB-D2FF-4E79-BE01-EB120E8E1F50Q36755236-0123DCC2-72AF-4E78-A00F-82E987A7EE7AQ36930572-C20A2AD0-B90D-430A-B1A1-4DE6D1F6A519Q37345488-ABC3B8E8-EDF6-4DE7-BC2D-1D28A59D9CEBQ37703061-B528F214-3DA5-4C76-9929-98B891B12F2CQ37813704-803948B2-4723-4A2A-927E-DD021212C97BQ37955218-136C56AD-2178-4D16-AA6B-FBF5673AEB9DQ37980484-E613F32C-A1A4-4E97-88A1-60156A834D60Q38027577-0B5EBAC3-8075-4346-B748-FC2397548D54Q38159803-50CBEA1A-041F-4749-BBE9-35B661C4CBB1Q38257403-52111F61-473B-493A-8D75-D2249677DFC6Q38374072-DA2ACB4C-5DCA-4F99-87E8-F3643F4AACADQ38571849-B9BC1D01-527A-41BE-96F0-001FA8B9DCCBQ38675867-C5B2472A-8F39-4DCA-B897-A2D00D00E186Q38807000-2CD7478D-F5DA-4693-99CF-2192CF8501A5Q38969036-8B3E21E3-C8BA-4DCC-8100-23A1DD755D6AQ39004668-DF21FAE9-B038-4A5C-860D-C80DEA73C3D5Q39277950-51DC9DF2-BF42-4175-9A36-3E00E1FB7A74Q42090633-B72ED439-4EAD-4EEF-99DE-1A538CEF5479Q42210912-30553B3E-5A8A-4917-BE2D-A9D9E0617A3FQ42236159-C261C4EC-7A35-4AB6-AEDE-179DEA2F26DDQ44365951-BB6254D6-3DC3-4391-8DD6-50E712B4CA81Q46437505-F8D7A482-C711-4FE2-A35C-136E39B19618Q48132042-3CD568C5-570A-457C-BFAE-5FE786D620A0
P2860
Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Current status and new develop ...... hritis with biological agents.
@ast
Current status and new develop ...... hritis with biological agents.
@en
Current status and new develop ...... hritis with biological agents.
@nl
type
label
Current status and new develop ...... hritis with biological agents.
@ast
Current status and new develop ...... hritis with biological agents.
@en
Current status and new develop ...... hritis with biological agents.
@nl
prefLabel
Current status and new develop ...... hritis with biological agents.
@ast
Current status and new develop ...... hritis with biological agents.
@en
Current status and new develop ...... hritis with biological agents.
@nl
P2860
P1476
Current status and new develop ...... hritis with biological agents.
@en
P2093
Wolfgang Weger
P2860
P304
P356
10.1111/J.1476-5381.2010.00702.X
P407
P577
2010-06-01T00:00:00Z